Navigation Links
Study Finds QIAGEN's HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap
Date:5/21/2008

HILDEN, Germany, May 21 /PRNewswire-FirstCall/ --

- Research Supports Replacement of Pap With HPV Test as Front-line Screen

Long-term data from a study published in the International Journal of Cancer show that women screened only with a human papillomavirus (HPV) DNA test are half as likely to develop moderate to severe cervical disease over the next six years as those who get only conventional cytology (the Pap "smear"). The research followed nearly 3,000 women age 35 years and older, and assessed their HPV status using QIAGEN's digene(R) HPV Test - the only such test that is both CE-marked in Europe and approved by the U.S. Food and Drug Administration (FDA).

"These results confirm that HPV DNA testing identifies more women with disease than the Pap," says Professor Jack Cuzick, lead author of the May 15 article and professor of epidemiology at the Wolfson Institute of Preventive Medicine, affiliated with Queen Mary's School of Medicine and Dentistry in London. "They add further support to the proposal to use HPV testing as the sole primary screen in women age 35 or older, when the risk of cervical cancer is highest."

Participants were recruited into the study from April 1994 to September 1997 at 40 different general-medicine practices in the United Kingdom. A colposcopy exam and biopsy were used to confirm or rule out the presence of cervical disease after each woman had both the HPV test and a conventional Pap. The sensitivity of the digene HPV Test was 96 percent for disease detected in the first year - substantially higher than the Pap's 82.4 percent. In addition to the HPV test's greater ability to accurately identify women with pre-cancerous cervical cells or cancer, its specificity (the likelihood that women with positive results actually have disease) was similar to that of the Pap.

Study results also showed that the women's risk of developing cervical abnormalities in the future were significantly less when they
'/>"/>

SOURCE Qiagen N V
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
2. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
3. Annual FIT Testing Detects Colorectal Cancer Two Years Earlier Than Colonoscopy Alone, Study of High-Risk Population Finds
4. Study Analyzed SYMBICORT(R) in Children with Persistent Asthma
5. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
6. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
7. Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW
8. Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma
9. Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
10. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
11. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015  The Partnership to Fight Chronic Disease (PFCD) released ... care leaders and a new study analyzing the impact of increased ... a nationwide coalition working to educate policy makers and the public ... Capitol was focused on how the Iowa ...
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Immune Therapeutics, ... Global Biotechnology, Inc. for the compounding, packaging and distributing of ... in the United States . ... capable of compounding naltrexone tablets in various strengths for individual ...
(Date:1/23/2015)... , Jan. 23, 2015  iMD Companies, Inc. (ICBU) has ... increase market share and grab a foothold in the hydroponic, ... production capabilities and a presence in the sector, and recently ... the growth of hemp and medical marijuana, iMD is committing ...
Breaking Medicine Technology:New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2
... China, April 19, 2011 /PRNewswire-Asia-FirstCall/ -- China Botanic ... ("China Botanic" or the "Company"), a developer, manufacturer ... Chinese medicines ("TCM") in China, today announced that ... owned subsidiary, Harbin Renhuang Pharmaceutical Co., Ltd ("Renhuang"), ...
... April 19, 2011 Cumberland Pharmaceuticals Inc. ... focused on hospital acute care and gastroenterology markets, today ... acquire the rights to ifetroban, a new Phase II ... the brand name Hepatoren™ (ifetroban) Injection and is evaluating ...
Cached Medicine Technology:China Botanic Pharmaceutical Provides Update on Badger Oil Sales 2China Botanic Pharmaceutical Provides Update on Badger Oil Sales 3Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 2Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 3Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 4
(Date:1/22/2015)... A new white paper by The Beryl Institute ... long-term care environment as well as provides recommendations for ... “The Power of Person-Centeredness in Long-Term Care: A View ... patient, resident and family experience in long-term care and ...
(Date:1/22/2015)... January 22, 2015 For over 20 years, Dr. ... Oceanside and Vista area has treated just about every type ... injury circumstances. And for those same twenty-plus years, the team ... all those injuries with the best possible doctor. With ...
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 ... of Sports Medicine flagship journal Medicine & Science ... L-Citrulline before exercise may help reduce gastrointestinal (GI) ... 1 , Participants in the double-blind, placebo-controlled ...
(Date:1/22/2015)... City, Florida (PRWEB) January 22, 2015 IsoComforter, ... cold therapy machine with patented IsoTube design to treat specific ... has introduced the most progressive and easy to use patented ... treat post-operative and sports related orthopedic and muscle injuries. ...
(Date:1/22/2015)... 2015 EBSCO Information Services (EBSCO) ... their relationship in an effort to further promote visibility and ... EBSCO has long made AMA journals available via its subscription ... The JAMA Network. , Long known as both ...
Breaking Medicine News(10 mins):Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... strengthen brand recognition, national ... BUFFALO, N.Y., Sept. 17 Meritain Health, ... today announced,the name change of recently acquired benefits ... of Meritain Health. Meritain Health acquired Weyco ...
... Va., Sept. 17 LifeNet Health, a leading,biomedical ... "The,Skin & Wound Allograft Institute" in affiliation with ... nation,s largest and most progressive,organ and tissue recovery ... & Wound Institute" will directly serve the needs ...
... affect asthma type, study concludes, , , MONDAY, Sept. ... affect the type of asthma you develop, new ... youngsters in affluent, developed countries had more allergy-triggered ... developed countries. , "The link between atopic ...
... 17, 2007 - In October the American College of ... Health." Edited by Dr. Harvey Makadon, Dr. Ken Mayer, ... Community Health, and Dr. Jennifer Potter of Beth Israel ... current and future medical providers about the unique health ...
... 17 Governor Edward G.,Rendell has appointed 37 individuals ... with chronic disease receive health care in the,future. The ... care reform plan. "About 78 percent of all ... of all patients -- those with chronic diseases,",Governor Rendell ...
... Michael E. Phillips MBA Offers Extensive Hospital, Financial and Capital ... ... Sheets: GSIEF) is pleased to announce that Michael E. Phillips,has been elected ... brings an important dimension to,GSI because of his crossover experience in both ...
Cached Medicine News:Health News:Meritain Health Announces Name Change for Acquired Companies 2Health News:LifeNet Health Establishes 'The Skin & Wound Allograft Institute' 2Health News:Allergy-Induced Asthma More Common in Affluent Countries 2Health News:Allergy-Induced Asthma More Common in Affluent Countries 3Health News:American College of Physicians publishes 'The Fenway Guide to LGBT Health' 2Health News:Governor Rendell Appoints Members of Chronic Care Commission as Part of Prescription for PA 2Health News:Governor Rendell Appoints Members of Chronic Care Commission as Part of Prescription for PA 3Health News:Governor Rendell Appoints Members of Chronic Care Commission as Part of Prescription for PA 4Health News:Governor Rendell Appoints Members of Chronic Care Commission as Part of Prescription for PA 5Health News:Fund Manager Joins Board of GSI Securitization Inc. 2
Microplate incubator shaker used in a variety of immunoassay and research procedures requiring microplates....
Multiparameter laser and arc lamp flow cytometer for all applications in immunology, microbiology, cell biology, pathology, hematology, lymphocyte dubset and cell analysis....
This unique system combines the analytical power of a research cytometer into a compact, truly walk away, clinical analyzer ergonomically designed to expedite sample throughput....
The Elecsys 2010 Rack System streamlines processes and allows for smooth implementation of laboratory automation....
Medicine Products: